The balance of angiotensin II and nitric oxide in kidney diseases

Current Opinion in Nephrology and Hypertension

Volumn 17, Issue 1, 2008, Pages 51-56

  Singh, Prabhleen ^a   Deng, Aihua ^a   Weir, Matthew R ^b   Blantz, Roland C ^a,c  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Acute kidney injury; Angiotensin II; Chronic kidney disease; Nitric oxide

Indexed keywords

ADENOSINE RECEPTOR BLOCKING AGENT; AMINO ACID; ANGIOTENSIN II; ANGIOTENSIN II ANTAGONIST; CONTRAST MEDIUM; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; GENTAMICIN; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR;

ACUTE KIDNEY FAILURE; CHRONIC KIDNEY DISEASE; CREATININE CLEARANCE; INFUSION; KIDNEY FUNCTION; METABOLIC BALANCE; NITROGEN BALANCE; NONHUMAN; OXYGEN CONSUMPTION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SEPSIS;

ANGIOTENSIN II; ANIMALS; HUMANS; KIDNEY DISEASES; KIDNEY FAILURE, ACUTE; KIDNEY FAILURE, CHRONIC; NITRIC OXIDE;

EID: 37349091476     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNH.0b013e3282f29a8b     Document Type: Review

References (89)

1. Patzak A, Persson AE. Angiotensin II-nitric oxide interaction in the kidney. Curr Opin Nephrol Hypertens 2007; 16:46-51. This article discusses the interactions of angiotensin II and nitric oxide in the control of renal blood flow, tubuloglomerular feedback and filtration, and the role of angiotensin II type 1 and type 2 receptors in the release of nitric oxide. Recent data on the modulation of the angiotensin II-nitric oxide interactions by reactive oxygen species in angiotensin II-dependent hypertension models are also reviewed.
2. Blantz RC, Deng A, Lortie M, et al. The complex role of nitric oxide in the regulation of glomerular ultrafiltration. Kidney Int 2002; 61:782-785.
3. Vaziri ND, Ni Z, Wang XQ, et al. Downregulation of nitric oxide synthase in chronic renal insufficiency: role of excess PTH. Am J Physiol 1998; 274 (4 Pt 2):F642-F649.
4. Aiello S, Noris M, Todeschini M, et al. Renal and systemic nitric oxide synthesis in rats with renal mass reduction. Kidney Int 1997; 52:171-181.
5. Roczniak A, Fryer JN, Levine DZ, Burns KD. Downregulation of neuronal nitric oxide synthase in the rat remnant kidney. J Am Soc Nephrol 1999; 10:704-713.
6. Wagner L, Riggleman A, Erdely A, et al. Reduced nitric oxide synthase activity in rats with chronic renal disease due to glomerulonephritis. Kidney Int 2002; 62:532-536.
7. Manotham K, Tanaka T, Matsumoto M, et al. Evidence of tubular hypoxia in the early phase in the remnant kidney model. J Am Soc Nephrol 2004; 15:1277-1288.
8. Palm F, Cederberg J, Hansell P, et al. Reactive oxygen species cause diabetes-induced decrease in renal oxygen tension. Diabetologia 2003; 46:1153-1160.
9. Welch WJ, Baumgartl H, Lubbers D, Wilcox CS. Renal oxygenation defects in the spontaneously hypertensive rat: role of AT1 receptors. Kidney Int 2003; 63:202-208.
10. Onozato ML, Tojo A, Goto A, et al. Oxidative stress and nitric oxide synthase in rat diabetic nephropathy: effects of ACEI and ARB. Kidney Int 2002; 61:186-194.
11. Can C, Sen S, Boztok N, Tuglular I. Protective effect of oral L-arginine administration on gentamicin-induced renal failure in rats. Eur J Pharmacol 2000; 390:327-334.
12. Rivas-Cabanero L, Montero A, Lopez-Novoa JM. Increased glomerular nitric oxide synthesis in gentamicin-induced renal failure. Eur J Pharmacol 1994; 270:119-121.
13. Yamada M, Hishida A, Honda N. Effects of desoxycorticosterone acetate (DOCA) plus saline drinking on gentamicin-mediated nephropathy in rats. Ren Fail 1992; 14:499-505.
14. Bird JE, Milhoan K, Wilson CB, et al. Ischemic acute renal failure and antioxidant therapy in the rat. The relation between glomerular and tubular dysfunction. J Clin Invest 1988; 81:1630-1638.
15. Adler S, Huang H. Oxidant stress in kidneys of spontaneously hypertensive rats involves both oxidase overexpression and loss of extracellular superoxide dismutase. Am J Physiol Renal Physiol 2004; 287:F907-F913.
16. Lopez B, Salom MG, Arregui B, et al. Role of superoxide in modulating the renal effects of angiotensin II. Hypertension 2003; 42:1150-1156.
17. Mollnau H, Wendt M, Szocs K, et al. Effects of angiotensin II infusion on the expression and function of NAD(P)H oxidase and components of nitric oxide/cGMP signaling. Circ Res 2002; 90:E58-E65.
18. Agmon Y, Peleg H, Greenfeld Z, et al. Nitric oxide and prostanoids protect the renal outer medulla from radiocontrast toxicity in the rat. J Clin Invest 1994; 94:1069-1075.
19. Brezis M, Greenfeld Z, Shina A, Rosen S. Angiotensin II augments medullary hypoxia and predisposes to acute renal failure. Eur J Clin Invest 1990; 20:199-207.
20. Wang W, Falk SA, Jittikanont S, et al. Protective effect of renal denervation on normotensive endotoxemia-induced acute renal failure in mice. Am J Physiol Renal Physiol 2002; 283:F583-F587.
21. Schwartz D, Mendonca M, Schwartz I, et al. Inhibition of constitutive nitric oxide synthase (NOS) by nitric oxide generated by inducible NOS after lipopolysaccharide administration provokes renal dysfunction in rats. J Clin Invest 1997; 100:439-448.
22. Wang W, Zolty E, Falk S, et al. Prostacyclin in endotoxemia-induced acute kidney injury: cyclooxygenase inhibition and renal prostacyclin synthase transgenic mice. Am J Physiol Renal Physiol 2007; 293:F1131-F1136. The authors attempt to elucidate the protective role of prostacyclin (PGI2) in endotoxemia-related kidney injury. Higher renal cyclic AMP levels were found in the transgenic mice, however, compared with wild-type mice and enalapril pretreatment before LPS administration in the transgenic mice significantly improved GFR in the PGI2 transgenic mice, while no effect was observed in wild-type mice.
23. Coresh J, Astor BC, Greene T, et al. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003; 41:1-12.
24. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351:1296-1305.
25. Remuzzi G, Benigni A, Remuzzi A. Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J Clin Invest 2006; 116:288-296.
26. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329:1456-1462.
27. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345:851-860.
28. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345:861-869.
29. de Zeeuw D, Remuzzi G, Parving HH, et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 2004; 65:2309-2320.
30. Baylis C, Mitruka B, Deng A. Chronic blockade of nitric oxide synthesis in the rat produces systemic hypertension and glomerular damage. J Clin Invest 1992; 90:278-281.
31. Schmidt RJ, Yokota S, Tracy TS, et al. Nitric oxide production is low in end-stage renal disease patients on peritoneal dialysis. Am J Physiol 1999; 276 (5 Pt 2):F794-F797.
32. Schmidt RJ, Domico J, Samsell LS, et al. Indices of activity of the nitric oxide system in hemodialysis patients. Am J Kidney Dis 1999; 34:228-234.
33. Schmidt RJ, Baylis C. Total nitric oxide production is low in patients with chronic renal disease. Kidney Int 2000; 58:1261-1266.
34. Blum M, Yachnin T, Wollman Y, et al. Low nitric oxide production in patients with chronic renal failure. Nephron 1998; 79:265-268.
35. Wever R, Boer P, Hijmering M, et al. Nitric oxide production is reduced in patients with chronic renal failure. Arterioscler Thromb Vasc Biol 1999; 19:1168-1172.
36. Baylis C. Arginine, arginine analogs and nitric oxide production in chronic kidney disease. Nat Clin Pract Nephrol 2006; 2:209-220. This article reviews the various mechanisms that lead to decreased nitric oxide generation and availability in chronic kidney disease and end-stage renal disease focusing on the aspects of substrate (L-arginine) limitation and increased levels of endogenous inhibitors of nitric oxide synthase (asymmetric dimethylarginine).
37. Tizianello A, De Ferrari G, Garibotto G, et al. Renal metabolism of amino acids and ammonia in subjects with normal renal function and in patients with chronic renal insufficiency. J Clin Invest 1980; 65:1162-1173.
38. Reyes AA, Karl IE, Klahr S. Role of arginine in health and in renal disease. Am J Physiol 1994; 267 (3 Pt 2):F331-F346.
39. Xiao S, Wagner L, Mahaney J, Baylis C. Uremic levels of urea inhibit L-arginine transport in cultured endothelial cells. Am J Physiol Renal Physiol 2001; 280:F989-F995.
40. Wagner L, Klein JD, Sands JM, Baylis C. Urea transporters are distributed in endothelial cells and mediate inhibition of L-arginine transport. Am J Physiol Renal Physiol 2002; 283:F578-F582.
41. Vallance P, Leone A, Calver A, et al. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992; 339:572-575.
42. Fleck C, Janz A, Schweitzer F, et al. Serum concentrations of asymmetric (ADMA) and symmetric (SDMA) dimethylarginine in renal failure patients. Kidney Int Suppl 2001; 78:S14-S18.
43. Schwartz IF, Ayalon R, Chernichovski T, et al. Arginine uptake is attenuated through modulation of cationic amino-acid transporter-1, in uremic rats. Kidney Int 2006; 69:298-303.
44. Bosch JP, Saccaggi A, Lauer A, et al. Renal functional reserve in humans. Effect of protein intake on glomerular filtration rate. Am J Med 1983; 75:943-950.
45. Meyer TW, Ichikawa I, Zatz R, Brenner BM. The renal hemodynamic response to amino acid infusion in the rat. Trans Assoc Am Physicians 1983; 96:76-83.
46. Castellino P, Coda B, DeFronzo RA. Effect of amino acid infusion on renal hemodynamics in humans. Am J Physiol 1986; 251 (1 Pt 2):F132-F140.
47. King AJ, Troy JL, Anderson S, et al. Nitric oxide: a potential mediator of amino acid-induced renal hyperemia and hyperfiltration. J Am Soc Nephrol 1991; 1:1271-1277.
48. Tolins JP, Raij L. Effects of amino acid infusion on renal hemodynamics. Role of endothelium-derived relaxing factor. Hypertension 1991; 17 (6 Pt 2):1045-1051.
49. De Nicola L, Blantz RC, Gabbai FB. Nitric oxide and angiotensin II. Glomerular and tubular interaction in the rat. J Clin Invest 1992; 89:1248-1256.
50. De Nicola L, Blantz RC, Gabbai FB. Renal functional reserve in treated and untreated hypertensive rats. Kidney Int 1991; 40:406-412.
51. De Nicola L, Blantz RC, Gabbai FB. Renal functional reserve in the early stage of experimental diabetes. Diabetes 1992; 41:267-273.
52. De Nicola L, Keiser JA, Blantz RC, Gabbai FB. Angiotensin II and renal functional reserve in rats with Goldblatt hypertension. Hypertension 1992; 19(6 Pt 2):790-794.
53. De Nicola L, Thomson SC, Wead LM, et al. Arginine feeding modifies cyclosporine nephrotoxicity in rats. J Clin Invest 1993; 92:1859-1865.
54. DeNicola L, Peterson OW, Obagi S, et al. Renal functional reserve in experimental chronic glomerulonephritis. Nephrol Dial Transplant 1994; 9:1383-1389.
55. Giugliano D, Marfella R, Verrazzo G, et al. The vascular effects of L-Arginine in humans. The role of endogenous insulin. J Clin Invest 1997; 99:433-438.
56. Gabbai FB, De Nicola L, Garcia GE, Blantz RC. Role of angiotensin in the regulation of renal response to proteins. Semin Nephrol 1995; 15:396-404.
57. Garcia GE, Hammond TC, Wead LM, et al. Effect of angiotensin II on the renal response to amino acid in rats. Am J Kidney Dis 1996; 28:115-123.
58. Schurek HJ, Jost U, Baumgartl H, et al. Evidence for a preglomerular oxygen diffusion shunt in rat renal cortex. Am J Physiol 1990; 259 (6 Pt 2):F910-F915.
59. Schurek HJ. Kidney medullary hypoxia: a key to understanding acute renal failure? Klin Wochenschr 1988; 66:828-835.
60. Klahr S, Hamm L, Hammerman MR, Mandel LJ. Renal metabolism: integrated responses. In: Windhager EE, editor. Handbook of physiology (Section 8: Renal Physiology). Oxford: Oxford University Press; 1992. pp. 2263-2334.
61. Tucker BJ, Blantz RC. An analysis of the determinants of nephron filtration rate. Am J Physiol Renal Physiol 1977; 232:F477-F483.
62. Tucker BJ, Blantz RC. Factors determining superficial nephron filtration in the mature, growing rat. Am J Physiol 1977; 232:F97-F104.
63. Thurau K. Renal Na-reabsorption and O2-uptake in dogs during hypoxia and hydrochlorothiazide infusion. Proc Soc Exp Biol Med 1961; 106:714-717.
64. Deetjen P, Kramer K. The relation of O2 consumption by the kidney to Na reresorption. Pflugers Arch Gesamte Physiol Menschen Tiere 1961; 273:636-650.
65. Kang DH, Kanellis J, Hugo C, et al. Role of the microvascular endothelium in progressive renal disease. J Am Soc Nephrol 2002; 13:806-816.
66. Nangaku M. Chronic hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure. J Am Soc Nephrol 2006; 17:17-25. In this article, the author discusses the role of chronic hypoxia in the tubulointerstitium as the common final pathway to progressive kidney disease. Evidence for various pathogenic mechanisms leading to chronic hypoxia such as loss of peritubular capillaries, imbalances in vasoactive substances, increased oxidative stress and increased metabolic demands are reviewed.
67. Eckardt KU, Bernhardt WM, Weidemann A, et al. Role of hypoxia in the pathogenesis of renal disease. Kidney Int Suppl 2005; 99:S46-S51.
68. Deng A, Thomson SC, Blantz RC. Oxygen consumption in 5/6th nephrectomized kidney: Effects of ANG II [abstract]. J Am Soc Nephrol 2006; 17:210A.
69. Deng A, Miracle CM, Suarez JM, et al. Oxygen consumption in the kidney: effects of nitric oxide synthase isoforms and angiotensin II. Kidney Int 2005; 68:723-730.
70. Norman JT, Fine LG. Intrarenal oxygenation in chronic renal failure. Clin Exp Pharmacol Physiol 2006; 33:989-996. This paper reviews the evidence for the association of hypoxia with chronic renal failure in different animal models. Regulation of various genes by hypoxia and its role in induction of profibrotic cytokines and sustained inflammation is discussed.
71. Korner A, Eklof AC, Celsi G, Aperia A. Increased renal metabolism in diabetes. Mechanism and functional implications. Diabetes 1994; 43:629-633.
72. Palm F, Hansell P, Ronquist G, et al. Polyol-pathway-dependent disturbances in renal medullary metabolism in experimental insulin-deficient diabetes mellitus in rats. Diabetologia 2004; 47:1223-1231.
73. Palm F. Intrarenal oxygen in diabetes and a possible link to diabetic nephropathy. Clin Exp Pharmacol Physiol 2006; 33:997-1001. The author reviews the findings from recent studies on the link between hyperglycemia and alterations in renal oxygen metabolism and decreased renal oxygen availability, which involves decreased nitric oxide bioavailability as a result of increased reactive oxygen species formation.
74. Welch WJ. Intrarenal oxygen and hypertension. Clin Exp Pharmacol Physiol 2006; 33:1002-1005. In this article, the relationship between renal oxygen tension, oxygen consumption and hypertension is discussed. The author presents evidence for inefficient renal oxygen consumption for the transport of sodium in the spontaneously hypertensive rat model and normalization of this after treatment with angiotensin receptor blocker.
75. Buerk DG. Can we model nitric oxide biotransport? A survey of mathematical models for a simple diatomic molecule with surprisingly complex biological activities. Annu Rev Biomed Eng 2001; 3:109-143.
76. Palm F, Buerk DG, Carlsson PO, et al. Reduced nitric oxide concentration in the renal cortex of streptozotocin-induced diabetic rats: effects on renal oxygenation and microcirculation. Diabetes 2005; 54:3282-3287.
77. Koivisto A, Pittner J, Froelich M, Persson AE. Oxygen-dependent inhibition of respiration in isolated renal tubules by nitric oxide. Kidney Int 1999; 55:2368-2375.
78. Echtay KS, Murphy MP, Smith RA, et al. Superoxide activates mitochondrial uncoupling protein 2 from the matrix side. Studies using targeted antioxidants. J Biol Chem 2002; 277:47129-47135.
79. Asaba K, Tojo A, Onozato ML, et al. Effects of NADPH oxidase inhibitor in diabetic nephropathy. Kidney Int 2005; 67:1890-1898.
80. Thomson SC, Deng A, Komine N, et al. Early diabetes as a model for testing the regulation of juxtaglomerular NOS I. Am J Physiol Renal Physiol 2004; 287:F732-F738.
81. Miracle CM, Deng A, Blantz RC, Thomson SC. NOS-1 tonically suppresses oxygen consumption in the diabetic rat kidney. FASEB J 2005; 19:A155.
82. Laycock SK, Vogel T, Forfia PR, et al. Role of nitric oxide in the control of renal oxygen consumption and the regulation of chemical work in the kidney. Circ Res 1998; 82:1263-1271.
83. Peterson OW, Gabbai FB, Myers RR, et al. A single nephron model of acute tubular injury: role of tubuloglomerular feedback. Kidney Int 1989; 36:1037-1044.
84. Ali BH. Gentamicin nephrotoxicity in humans and animals: some recent research. Gen Pharmacol 1995; 26:1477-1487.
85. Hishida A, Nakajima T, Yamada M, et al. Roles of hemodynamic and tubular factors in gentamicin-mediated nephropathy. Ren Fail 1994; 16:109-116.
86. Chabrashvili T, Kitiyakara C, Blau J, et al. Effects of ANG II type 1 and 2 receptors on oxidative stress, renal NADPH oxidase, and SOD expression. Am J Physiol Regul Integr Comp Physiol 2003; 285:R117-R124.
87. Heyman SN, Rosenberger C, Rosen S. Regional alterations in renal haemodynamics and oxygenation: a role in contrast medium-induced nephropathy. Nephrol Dial Transplant 2005; 20 (Suppl 1):i6-i11.
88. Brezis M, Heyman SN, Dinour D, et al. Role of nitric oxide in renal medullary oxygenation. Studies in isolated and intact rat kidneys. J Clin Invest 1991; 88:390-395.
89. Erley CM, Heyne N, Burgert K, et al. Prevention of radiocontrast-induced nephropathy by adenosine antagonists in rats with chronic nitric oxide deficiency. J Am Soc Nephrol 1997; 8:1125-1132.